2303119
Last Update Posted: 2023-01-10
Recruiting has ended
All Genders accepted | 18 Years + |
221 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
Patient will receive either one infusion of rituximab IV and seven administrations of rituximab SC (experimental arm) or four infusions of rituximab IV (standard arm).
The hypothesis is that the use of rituximab by sub cutaneous route and the scheme of administration could:
- optimize rituximab exposure leading to improve response rate
- increase adaptative response and then improve long-term control disease.
Eligibility
Relevant conditions:
Follicular Lymphoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov